Skip to Main Content

Paper Details

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer.
JCO Precis Oncol
19
2021
Author NameAffiliation
Caroline E McCoachHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Primo N LaraUniversity of California Davis Comprehensive Cancer Center
Matthew A GubensHelen Diller Family Comprehensive Cancer Center, University of California san francisco
Laurel A BeckettUniversity of California Davis Comprehensive Cancer Center
  • 1 - 4

Datasets

Release 1.2